Bara Badwan

Data Scientist at Intelligencia AI      


Contributing Author   in
AI & Digital  

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Articles from Bara

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

   1723
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often going public before generating revenue, valuations hinge on the potential for FDA approval of their assets. Herein lies the power of artificial intelligence (AI): by predicting the likelihood of success for these assets, we can uncover undervalued companies, offering a strategic edge not only to hedge funds and VCs but also to big pharma companies considering acquisitions. In this dynamic landscape, projected to see M&A activities reaching as high as $275B in 2024, the ability to discern and invest in promising biotech assets early is crucial.